NIMS' Modified AT-101(TM) Motion Platform Device Superior to Mechanical Closed Chest Message Device in CPR.

NORTH BAY VILLAGE, Fla. -- Gary Macleod, Chief Executive Officer, Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU) announced report of a research study of a modification of NIMS' flagship, patented product, the AT-101(TM), which demonstrated superior outcomes than a standard closed chest message device for cardiopulmonary resuscitation (CPR). This investigation by Dr. Wu and associates from Mt. Sinai Medical Center of Greater Miami was published in the September 2006 issue of Resuscitation.

Dr. Marvin Sackner, Chairman of the Board of Directors stated that, "the AT-101(TM) for human use is a platform that repetitively moves a supine person lying on a mattress in a head to foot direction at about 140 times a minute with a displacement of 3/4 inch or less over a period of 30 to 45 minutes. A clinical trial is planned to support its intended use of temporary relief of musculoskeletal pain associated with osteoarthritis of the hips in order to meet FDA approval for its marketing."

In the study of a large animal model by Dr. Wu and associates, stoppage of the heart was induced in two groups for about 18 minutes while either a modified AT-101(TM) motion platform (stronger force than the human device) or a closed chest massage device (Thumper(R)) was employed. Survival rates for the two groups was the same but the AT-101(TM) group showed significantly better cardiac function and less signs of inflammation hours after resuscitation than the Thumper group. The authors suggest that this new technology "could possibly be used as a viable alternative to conventional chest compression."

Dr. Jose A. Adams, senior investigator of the group stated, "these findings suggest that the AT-101(TM) technology which causes release of nitric oxide and prostacylin into the circulation during heart stoppage may 'condition' the heart and other organs to minimize the known adverse effects of damage caused after circulation is re-established, a phenomenon called ischemia/reperfusion injury." He added that, "ischemia/reperfusion injury can occur after treatment of acute blood loss and sepsis, and, following heart attacks and strokes but a great deal more research needs to be done before this indication can be advocated for a clinical trial."

The AT-101(TM) is not currently being sold in the United States pending FDA approval. A clinical trial is planned for its intended use of temporary relief of musculoskeletal pain associated with osteoarthritis of the hips.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.